Eli Lilly Has A Solid Upside Now After Its Q3 Earnings

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

US stocks sink as Wall Street sees both good and bad in Big Tech profits, US-China relations

NEW YORK (AP) — The U.S. stock market sank from its record heights on Thursday, as Wall Street sifted through mixed ...

Eli Lilly says weight-loss pill a candidate for speedy approval under new US program

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
BioSpace

Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...
Blockonomi

Pfizer (PFE) Stock: Pharma Giant Battles Novo Nordisk Over $9 Billion Metsera Deal

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Can a weight loss and diabetes drug treat long COVID?

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

Markets News, Oct. 30, 2025: Major Indexes Close Sharply Lower as Tech Stocks Slide; Meta, Microsoft Drop After Earnings

Major stock indexes declined Thursday as investors digested several big tech earnings reports and awaited more after the ...
EconoTimes

Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand

Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...

Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...